"The reason why the price point of the product was dropped in late 2012 from $399 to $99, and we were losing money on those kits, was that we believed once the database got to scale – it was hard to know what that magic number was – we would start to see real value. That was a significant bet. And once we saw real value, we knew there were multiple ways that we would be able to monetize it."
Andy Page, CEO, 23andme, on news that the company has put together a new therapeutics group

". . . nothing I can point to on the horizon that is going to slow this sector down. The investors right now are saying they're swamped with the number of deals in the marketplace, testing the waters pre-IPO as well as secondary and follow-on offerings."
Andrew McDonald, founding partner at Lifesci advisors, on the hot market for follow-on financings

"Taking an idea from a university and turning it into a commercial enterprise takes time. The five to 10 years required is too much for VCs. We are supplying long-term, patient capital."
Greg Smith, chief financial officer, IP Group plc, on raising $193 million in an oversubscribed placing